Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-31falsefalsefalse2025-01-014842false 07590062 2025-01-01 2025-12-31 07590062 2024-01-01 2024-12-31 07590062 2025-12-31 07590062 2024-12-31 07590062 2024-01-01 07590062 c:PriorPeriodIncreaseDecrease 2024-01-01 2024-12-31 07590062 1 2025-01-01 2025-12-31 07590062 1 2024-01-01 2024-12-31 07590062 3 2025-01-01 2025-12-31 07590062 3 2024-01-01 2024-12-31 07590062 4 2025-01-01 2025-12-31 07590062 4 2024-01-01 2024-12-31 07590062 5 2025-01-01 2025-12-31 07590062 5 2024-01-01 2024-12-31 07590062 1 2025-01-01 2025-12-31 07590062 e:Director1 2025-01-01 2025-12-31 07590062 e:Director2 2025-01-01 2025-12-31 07590062 e:Director3 2025-01-01 2025-12-31 07590062 e:RegisteredOffice 2025-01-01 2025-12-31 07590062 c:FurnitureFittings 2025-01-01 2025-12-31 07590062 c:FurnitureFittings 2025-12-31 07590062 c:FurnitureFittings 2024-12-31 07590062 c:FurnitureFittings c:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 07590062 c:CurrentFinancialInstruments 2025-12-31 07590062 c:CurrentFinancialInstruments 2024-12-31 07590062 c:CurrentFinancialInstruments c:WithinOneYear 2025-12-31 07590062 c:CurrentFinancialInstruments c:WithinOneYear 2024-12-31 07590062 c:ReportableOperatingSegment1 2025-01-01 2025-12-31 07590062 c:ReportableOperatingSegment1 2024-01-01 2024-12-31 07590062 f:UnitedKingdom 2025-01-01 2025-12-31 07590062 f:UnitedKingdom 2024-01-01 2024-12-31 07590062 f:RestEuropeOutsideUK 2025-01-01 2025-12-31 07590062 f:RestEuropeOutsideUK 2024-01-01 2024-12-31 07590062 f:RestWorldOutsideUK 2025-01-01 2025-12-31 07590062 f:RestWorldOutsideUK 2024-01-01 2024-12-31 07590062 c:ShareCapital 2025-12-31 07590062 c:ShareCapital 2024-12-31 07590062 c:ShareCapital 2024-01-01 07590062 c:MergerReserve 2025-01-01 2025-12-31 07590062 c:MergerReserve 2025-12-31 07590062 c:MergerReserve 3 2025-01-01 2025-12-31 07590062 c:MergerReserve 2024-12-31 07590062 c:MergerReserve c:PriorPeriodIncreaseDecrease 2024-01-01 2024-12-31 07590062 c:MergerReserve 2024-01-01 07590062 c:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 07590062 c:RetainedEarningsAccumulatedLosses 2025-12-31 07590062 c:RetainedEarningsAccumulatedLosses 3 2025-01-01 2025-12-31 07590062 c:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 07590062 c:RetainedEarningsAccumulatedLosses 2024-12-31 07590062 c:RetainedEarningsAccumulatedLosses c:PriorPeriodIncreaseDecrease 2024-01-01 2024-12-31 07590062 c:RetainedEarningsAccumulatedLosses 2024-01-01 07590062 c:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2025-12-31 07590062 c:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2024-12-31 07590062 c:FinancialLiabilitiesFairValueThroughProfitOrLoss c:ListedExchangeTraded 2025-12-31 07590062 c:FinancialLiabilitiesFairValueThroughProfitOrLoss c:ListedExchangeTraded 2024-12-31 07590062 e:OrdinaryShareClass1 2025-01-01 2025-12-31 07590062 e:OrdinaryShareClass1 2024-01-01 2024-12-31 07590062 e:OrdinaryShareClass1 2025-12-31 07590062 e:OrdinaryShareClass1 2024-12-31 07590062 e:FRS102 2025-01-01 2025-12-31 07590062 e:Audited 2025-01-01 2025-12-31 07590062 e:FullAccounts 2025-01-01 2025-12-31 07590062 e:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 07590062 c:Subsidiary1 2025-01-01 2025-12-31 07590062 c:Subsidiary1 1 2025-01-01 2025-12-31 07590062 c:WithinOneYear 2025-12-31 07590062 c:WithinOneYear 2024-12-31 07590062 c:BetweenOneFiveYears 2025-12-31 07590062 c:BetweenOneFiveYears 2024-12-31 07590062 2 2025-01-01 2025-12-31 07590062 6 2025-01-01 2025-12-31 07590062 c:ShareCapital 3 2025-01-01 2025-12-31 07590062 g:PoundSterling 2025-01-01 2025-12-31 07590062 c:ShareCapital c:PriorPeriodErrorIncreaseDecrease 2024-01-01 2024-12-31 07590062 c:RetainedEarningsAccumulatedLosses c:PreviouslyStatedAmount 2024-01-01 07590062 c:PreviouslyStatedAmount 2024-01-01 iso4217:GBP xbrli:shares xbrli:pure




















Remote Medical International UK Ltd

Registered number: 07590062
Annual Report
For the year ended 31 December 2025

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
COMPANY INFORMATION


Directors
D Higham 
I J Onstad 
J R Rawles 




Registered number
07590062



Registered office
4500 Parkway
Solent Business Park

Whiteley

Fareham

England

PO15 7AZ




Independent auditors
Forvis Mazars LLP
Chartered Accountants & Statutory Auditor

5th Floor

Merck House

Seldown Lane

Poole

BH15 1TW





 
REMOTE MEDICAL INTERNATIONAL UK LTD
 

CONTENTS



Page
Strategic Report
 
1 - 2
Directors' Report
 
3 - 5
Independent Auditors' Report
 
6 - 9
Statement of Comprehensive Income
 
10
Statement of Financial Position
 
11
Statement of Changes in Equity
 
12
Statement of Cash Flows
 
13 - 14
Notes to the Financial Statements
 
15 - 31


 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025

Introduction
 
The Directors present their Strategic Report and the audited financial statements of the Company for the year ended 31 December 2025.
Principal Activities
The Company’s principal activity is the provision of support for operations in complex environments, managing risk through the provision of medical, security and technical services.
Business review
The year to December 2025 saw the Company continue to focus on operational efficiencies and developing the business in its traditional markets and expanding operations into new areas.
The Company’s turnover remained steady year on year in line with expectations, gross margin increased to 32.72% (2024: 31.65%). Operating expenses increased during the year, reflecting the continued investment in the business and support functions, while the Company remained focused on operational efficiencies and improving gross margin.
The Company transferred its Brazilian subsidiary, RMI Global Solutions Brazil LTDA, to Remote Medicine Inc. shortly before the year end as part of cross border group streamlining and is in the process of transferring the RMI Global Solutions Guyana subsidiary in 2026.

Business Summary £m
2025
2025 % of Revenue
2024
2024 % of Revenue
Turnover
10.4

10.2

Gross Margin
3.4
33
3.2
32
Operating Expenses
5.2
50
4.7
46

Principal Risks and Uncertainties 
The Company operates in a competitive market and works to support our clients with our excellent quality of service and to develop lasting client relationships. 
A significant risk for the Company is the availability of the necessary talent to meet client needs in an extremely competitive market. Our Talent team works closely with our providers to maintain existing relationships and the Company has invested in the team to ensure we continue to attract the required personnel. 
During 2025 the Directors continued to work with the RMI teams to address the cost base and improve efficiency, as evidenced by the improved gross margin. This continues to give the Company a strong foundation for future growth. 
Liquidity Risk 
The Company manages liquidity risk by monitoring working capital requirements and ensuring that sufficient funds are available to meet liabilities as they fall due. This assessment includes consideration of cash forecasts, intercompany balances and the availability of shareholder support where required.
Credit Risk 
The Company’s principal credit risk arises from trade debtors, which totalled £1.4m at 31 December 2025 (2024: £2.1m). The Directors consider this exposure to be appropriately managed as the majority of customers are large, established organisations, and potential customers are financially reviewed before engagement.
 
- 1 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 

STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025

Interest Rate Risk 
The Company has no external borrowings, therefore no exposure to interest rate risk. 
Currency Risk 
The Company’s functional currency is Sterling; however, the business operates in many different currencies and actively manages currency risk by matching the currency of income to expenditure. 
Technology Risk 
During 2023, The Directors carried out a complete review of technology systems across the group, resulting in leaner more efficient systems capable of meeting our complex business needs and the Company continues to reap the benefits of these changes in 2025 through a process of continuous review and re-evaluation. 
Cyber and Information Security 
The Company retains strict systems security, working with our partners to maintain safety and security of information as well as system availability. 
Employee Engagement and communication 
The Company regularly engages with employees through “All Hands Meetings”, sharing strategy updates, business performance, successes, Company news and employee-related updates.
Future Developments 
In 2026, the Company continues to support its existing and new clients and the wider group business and plans to achieve a modest level of sustainable growth.


This report was approved by the board and signed on its behalf by:



D Higham
Director

Date: 14 August 2026

- 2 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025

The Directors present their report and the audited financial statements for the year ended 31 December 2025.

Principal activity

The Company’s principal activity is the provision of support for operations in complex environments, managing risk through the provision of medical, security and technical services.

Results and dividends

The loss for the year, after taxation, amounted to £1,939,902 (2024: £1,549,046).

Directors

The Directors who served during the year and to the date of this report were:

D Higham 
I J Onstad 
J R Rawles 

Directors' responsibilities statement

The Directors are responsible for preparing the Strategic Report, the Directors' Report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the Directors are required to:


∙select suitable accounting policies for the Company's financial statements and then apply them consistently;

∙make judgements and accounting estimates that are reasonable and prudent;

∙state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

- 3 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025

Economic impact of global events

UK businesses are facing many uncertainties and challenges caused by political, economic, social, technological, legal and environmental factors. These uncertainties have contributed to an environment where there exists a range of issues and risks, including inflation, rising interest rates, labour shortages, disrupted supply chains and new ways of working.
The Directors have carried out an assessment of the potential impact of these uncertainties on the business, including the impact of mitigation measures, and have concluded the greatest impact on the business is expected to be from the economic ripple effect on the global economy. The Directors have taken account of these potential impacts in their going concern assessment.
The Company continues to work with its partners to minimise any impacts of these events and maximise the realisation of any opportunities they may provide to the business.

Employee engagement and communication

The Company regularly engages with all employees through “All Hands Meetings”, sharing strategies, successes and Company and employee news. Our HR partner provides employee drop-in sessions and, in 2024 we have instigated group wide mental wellbeing training.

Going concern

The financial statements have been prepared on a going concern basis. As at 31 December 2025, the Company had net current liabilities of £4,406,536 (2024: £2,471,410) and net liabilities of £4,347,386 (2024: £2,459,601). Included within net current liabilities are net intercompany borrowings of £5,069,897 (2024: £4,014,311) which are repayable on demand. In the financial year, the Company incurred significant losses, which depleted retained earnings and increased liabilities, resulting in a net liability position. Post year end, the Company has continued to trade in line with expectations and forecasts prepared by management indicate that the Company will continue to be cash-generative to the end of the 2026 financial year and beyond into 2027.
In making their assessment, the Directors have given consideration to the financial position and performance of its parent company, Remote Medicine Inc. As noted in the consolidated financial statements of Remote Medicine Inc for the year ended 31 December 2025, the parent company has suffered recurring losses from operations, has a net capital deficiency, and expects to have negative cash flows from operations. The financial statements of Remote Medicine Inc include a material uncertainty related to going concern and therefore the ability to support the UK entity may be in doubt if required. Whilst the Company does acquire management and other business services from the parent company, it is not currently, and Directors do not foresee it becoming, reliant upon financial support from the parent company or the rest of the group. The group as a whole receives financial support from the ultimate shareholders when it is required.
However due to the financial position of the parent company and the inter-company borrowings, management has concluded that it is required to disclose that there is material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern for one year from the date of approval of these financial statements.
Whilst recognising the existence of this material uncertainty, having considered these factors and made all necessary inquiries, the Directors consider that the Company will continue to operate with sufficient cash headroom for a period of at least 12 months from the date of approval of these financial statements and conclude that it is appropriate to prepare the financial statements on a going concern basis.

- 4 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025

Qualifying third party indemnity provisions

The Company has made qualifying third party indemnity provisions for the benefit of its Directors which were made during the year and remain in force at the date of this report. No claim or notice of claim in respect of these indemnities has been received in the year. 

Matters covered in the Strategic Report

The Company has chosen in accordance with Companies Act 2006, s414C (11) to set out in the Company's Strategic Report information required by Schedule 7 to the Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008. Certain matters which are required to be disclosed in the Directors’ Report, including future developments, have been omitted as they are included in the Strategic Report.

Provision of information to the auditor

Each of the persons who are Directors at the time when this Directors' Report is approved has confirmed that:
 
∙so far as the Directors are aware, there is no relevant audit information of which the Company's auditors are unaware, and

∙the Directors have taken all the steps that ought to have been taken as a Director in order to be aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

Post balance sheet events

There have been no significant events affecting the Company since the year end.

Auditors

The auditors, Forvis Mazars LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the board and signed on its behalf by:
 



D Higham
Director

Date: 14 August 2026

- 5 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF REMOTE MEDICAL INTERNATIONAL UK LTD
 

Opinion

We have audited the financial statements of Remote Medical International UK Ltd (the ‘Company’) for the year ended 31 December 2025 which comprise the Statement of Comprehensive Income, the Statement of Financial Position, the Statement of Cash Flows, the Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. 
The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

∙give a true and fair view of the state of the Company’s affairs as at 31 December 2025 and of its loss for the year then ended;
∙have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
∙have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty relating to going concern 

We draw attention to note 2.2 in the financial statements, which indicates a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern. 
In auditing the financial statements, we have concluded that the Directors’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. As stated in note 2.2, the uncertainty around the financial position of the parent entity, along with the other matters set forth in note 2.2 indicate that a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern. Our opinion is not modified in respect to this matter. 

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The Directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
- 6 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF REMOTE MEDICAL INTERNATIONAL UK LTD
 

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:
 
∙the information given in the Strategic Report and the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the Strategic Report and the Directors' Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Directors' Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

∙adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
∙the financial statements are not in agreement with the accounting records and returns; or
∙certain disclosures of Directors' remuneration specified by law are not made; or
∙we have not received all the information and explanations we require for our audit.
 
Responsibilities of Directors

As explained more fully in the Directors' Responsibilities Statement set out on page 3, the Directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors intend either to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
 
- 7 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF REMOTE MEDICAL INTERNATIONAL UK LTD
 

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.
 
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. 

Based on our understanding of the Company and its industry, we considered that non-compliance with the following laws and regulations might have a material effect on the financial statements: employment regulation, health and safety regulation, anti-money laundering regulation.  

To help us identify instances of non-compliance with these laws and regulations, and in identifying and assessing the risks of material misstatement in respect to non-compliance, our procedures included, but were not limited to:
∙Inquiring of management and, where appropriate, those charged with governance, as to whether the Company is in compliance with laws and regulations, and discussing their policies and procedures regarding compliance with laws and regulations;
∙Inspecting correspondence, if any, with relevant licensing or regulatory authorities;
∙Communicating identified laws and regulations to the engagement team and remaining alert to any indications of non-compliance throughout our audit; and
∙Considering the risk of acts by the Company which were contrary to applicable laws and regulations, including fraud.  

We also considered those laws and regulations that have a direct effect on the preparation of the financial statements, such as tax legislation, pension legislation, the Companies Act 2006. 

In addition, we evaluated the Directors’ and management’s incentives and opportunities for fraudulent manipulation of the financial statements, including the risk of management override of controls, and determined that the principal risks related to posting manual journal entries to manipulate financial performance, management bias through judgements and assumptions in significant accounting estimates, revenue recognition (which we pinpointed to the occurrence assertion) and significant one-off or unusual transactions. 

Our audit procedures in relation to fraud included but were not limited to:
∙Making enquiries of the Directors and management on whether they had knowledge of any actual, suspected or alleged fraud;
∙Gaining an understanding of the internal controls established to mitigate risks related to fraud;
∙Discussing amongst the engagement team the risks of fraud; and
∙Addressing the risks of fraud through management override of controls by performing journal entry testing.

There are inherent limitations in the audit procedures described above and the primary responsibility for the prevention and detection of irregularities including fraud rests with management. As with any audit, there remained a risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal controls.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

- 8 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF REMOTE MEDICAL INTERNATIONAL UK LTD
 

Use of the audit report

This report is made solely to the Company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body for our audit work, for this report, or for the opinions we have formed.
 

Lesley Fox (Senior Statutory Auditor)
for and on behalf of Forvis Mazars LLP
Chartered Accountants and Statutory Auditor
5th Floor
Merck House
Seldown Lane
Poole
BH15 1TW

15 August 2026
- 9 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2025

2025
2024
Note
£
£

  

Turnover
 4 
10,368,430
10,239,952

Cost of sales
  
(6,975,381)
(6,999,060)

Gross profit
  
3,393,049
3,240,892

Administrative expenses
  
(5,175,273)
(4,678,484)

Operating loss
 5 
(1,782,224)
(1,437,592)

Interest receivable and similar income
 9 
1,256
18,501

Interest payable and similar expenses
 10 
(158,934)
(129,955)

Loss before tax
  
(1,939,902)
(1,549,046)

Tax on loss
 11 
-
-

Loss for the financial year
  
(1,939,902)
(1,549,046)

Other comprehensive income
  
-
-

Total comprehensive income for the year
  
(1,939,902)
(1,549,046)

There were no recognised gains and losses for 2025 or 2024 other than those included in the statement of comprehensive income.

The Statement of Comprehensive Income has been prepared on the basis that all operations are continuing operations.
The notes on pages 15 to 31 form part of these financial statements.

- 10 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
REGISTERED NUMBER: 07590062

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025

As restated
2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 12 
59,149
11,679

Investments
 13 
1
130

  
59,150
11,809

Current assets
  

Stocks
 14 
47,460
-

Debtors: amounts falling due within one year
 15 
2,378,480
6,120,194

Cash and cash equivalents
 16 
97,781
329,870

  
2,523,721
6,450,064

Creditors: amounts falling due within one year
 17 
(6,930,257)
(8,921,474)

Net current liabilities
  
 
 
(4,406,536)
 
 
(2,471,410)

Total assets less current liabilities
  
(4,347,386)
(2,459,601)

  

Net liabilities
  
(4,347,386)
(2,459,601)


Capital and reserves
  

Called up share capital 
 19 
1
1

Capital contribution reserve
 20 
52,117
-

Profit and loss account
 20 
(4,399,504)
(2,459,602)

  
(4,347,386)
(2,459,601)


The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



D Higham
Director

Date: 14 August 2026

The notes on pages 15 to 31 form part of these financial statements.

- 11 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025


Called up share capital
Capital contribution reserve
Profit and loss account
Total equity

£
£
£
£


At 1 January 2024 (as previously stated)
1
-
(1,594,069)
(1,594,068)

Prior year adjustment
-
-
683,513
683,513


At 1 January 2024 (as restated)
1
-
(910,556)
(910,555)



Loss for the year
-
-
(1,549,046)
(1,549,046)



At 1 January 2025
1
-
(2,459,602)
(2,459,601)



Loss for the year
-
-
(1,939,902)
(1,939,902)


Contributions by and distributions to owners

Capital contribution
-
52,117
-
52,117


At 31 December 2025
1
52,117
(4,399,504)
(4,347,386)


The notes on pages 15 to 31 form part of these financial statements.

- 12 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025

2025
2024
£
£

Cash flows from operating activities

Loss for the financial year
(1,939,902)
(1,549,046)

Adjustments for:

Depreciation of tangible assets
15,080
11,846

Interest paid
158,934
129,955

Interest received
(1,256)
(18,501)

(Increase)/decrease in stocks
(47,460)
-

Decrease/(increase) in debtors
897,521
(652,830)

Decrease/(increase) in amounts owed by groups
2,844,193
(201,009)

(Decrease) in creditors
(202,610)
(425)

(Decrease)/increase in amounts owed to groups
(1,788,607)
2,497,479

Capital contribution
52,117
-

Net cash generated from operating activities

(11,990)
217,469


Cash flows from investing activities

Purchase of tangible fixed assets
(70,566)
(16,956)

Sale of tangible fixed assets
8,016
-

Sale of fixed asset investments
129
-

Interest received
1,256
18,501

Net cash from investing activities

(61,165)
1,545

Cash flows from financing activities

Interest paid
(158,934)
(129,955)

Net cash used in financing activities
(158,934)
(129,955)

Net (decrease)/increase in cash and cash equivalents
(232,089)
89,059
- 13 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 

STATEMENT OF CASH FLOWS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025


2025
2024

£
£



Cash and cash equivalents at beginning of year
329,870
240,811

Cash and cash equivalents at the end of year
97,781
329,870


Cash and cash equivalents at the end of year comprise:

Cash at bank and in hand
97,781
329,870

97,781
329,870


The notes on pages 15 to 31 form part of these financial statements.

- 14 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


General information

Remote Medical International UK Ltd (the 'Company') is a private company limited by shares incorporated and registered in England and Wales. The Company's registered number is 07590062. The address of its registered office is 4500 Parkway, Solent Business Park, Whiteley, Fareham, England, PO15 7AZ. 
The principal activity of the Company is the provision of bespoke solutions supporting operations in complex environments and managing risk through medical, security and technical services. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.
The Company is a parent company that is also a subsidiary included in the consolidated financial statements of Remote Medicine Inc, a company incorporated in the USA which prepares consolidated financial statements under US GAAP. As such the Company is exempt from the requirement to prepare consolidated financial statements under section 401 of the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3).

The financial statements have been presented in Pound Sterling as this is the currency of the primary economic environment in which the Company operates and is rounded to the nearest pound.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on a going concern basis. As at 31 December 2025, the Company had net current liabilities of £4,406,536 (2024: £2,471,410) and net liabilities of £4,347,386 (2024: £2,459,601). Included within net current liabilities are net intercompany borrowings of £5,069,897 (2024: £4,014,311) which are repayable on demand. In the financial year, the Company incurred significant losses, which depleted retained earnings and increased liabilities, resulting in a net liability position. Post year end, the Company has continued to trade in line with expectations and forecasts prepared by management indicate that the Company will continue to be cash-generative to the end of the 2026 financial year and beyond into 2027.
In making their assessment, the Directors have given consideration to the financial position and performance of its parent company, Remote Medicine Inc. As noted in the consolidated financial statements of Remote Medicine Inc for the year ended 31 December 2025, the parent company has suffered recurring losses from operations, has a net capital deficiency, and expects to have negative cash flows from operations. The financial statements of Remote Medicine Inc include a material uncertainty related to going concern and therefore the ability to support the UK entity may be in doubt if required. Whilst the Company does acquire management and other business services from the parent company, it is not currently, and Directors do not foresee it becoming, reliant upon financial support from the parent company or the rest of the group. The group as a whole receives financial support from the ultimate shareholders when it is required.
 
- 15 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)


2.2
Going concern (continued)

However due to the financial position of the parent company and the inter-company borrowings, management has concluded that it is required to disclose that there is material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern for one year from the date of approval of these financial statements.
Whilst recognising the existence of this material uncertainty, having considered these factors and made all necessary inquiries, the Directors consider that the Company will continue to operate with sufficient cash headroom for a period of at least 12 months from the date of approval of these financial statements and conclude that it is appropriate to prepare the financial statements on a going concern basis.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentation currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss. 

All other foreign exchange gains and losses are presented in the Statement of Comprehensive Income within 'administrative expenses'. 

- 16 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.4

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Rendering of services

Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
∙the amount of turnover can be measured reliably;
∙it is probable that the Company will receive the consideration due under the contract;
∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and
∙the costs incurred and the costs to complete the contract can be measured reliably.

 
2.5

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.6

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.7

Interest payable and similar expenses

Interest payable and similar expenses are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.8

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

- 17 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.9

Share based payments

Where share options are awarded to employees, the fair value of the options at the date of grant is charged to the profit and loss account over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. The cumulative expense is not adjusted for failure to achieve a market vesting condition.
The fair value of the award also takes into account non-vesting conditions. These are either factors beyond the control of either party (such as a target based on an index) or factors which are within the control of one or other of the parties (such as the parent entity keeping the scheme scheme open or the employee maintaining any contributions required by the scheme). Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to the profit and loss account over the remaining vesting period.
Where equity instruments are granted to persons other than employees, profit or loss is charged with fair value of goods and services received.

 
2.10

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


- 18 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.11

Tangible assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

At each reporting date the Company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Furniture, fittings and equipment
-
15%
straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.12

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.13

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. 
At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.14

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

- 19 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.15

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

In the Statement of Cash Flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and form an integral part of the Company's cash management.

 
2.16

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.17

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.


3.


Judgements in applying accounting policies and key sources of estimation uncertainty

In applying the Company’s accounting policies, the Directors are required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The Directors’ judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be applicable. Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.
3.1 Critical judgements in applying the Company’s accounting policies
The critical judgements that the Directors have made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognised in the statutory financial statements are discussed below. 
(i) Assessing indicators of impairment
In assessing whether there have been any indicators of impairment of assets, the Directors have considered both external and internal sources of information such as market conditions and experience of recoverability. There have been no indicators of impairment identified during the current financial year. 
3.2 Key sources of estimation uncertainty
The key assumptions concerning the future, and other key sources of estimation uncertainty, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. 
 
- 20 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

3.Judgements in applying accounting policies (continued)


(i) Recoverability of debtors 
A provision for debtors is established where it is estimated that the debts are not considered to be fully recoverable. When assessing recoverability the Directors have considered factors such as the ageing of the debts, and past experience of recoverability. A provision of £37,627 has been recognised in the current financial year (2024: £59,550). 


4.


Turnover

An analysis of turnover by class of business is as follows:


2025
2024
£
£

Rendering of services
10,368,430
10,239,952


Analysis of turnover by country of destination:

2025
2024
£
£

United Kingdom
3,612,156
2,838,006

Europe
1,270,820
1,683,261

Rest of the world
5,485,454
5,718,685

10,368,430
10,239,952



5.


Operating loss

The operating loss is stated after charging:

2025
2024
£
£

Exchange differences
39,482
97,367

Depreciation of tangible assets
15,080
11,846

- 21 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

6.


Auditors' remuneration

During the year, the Company obtained the following services from the Company's auditors:


2025
2024
£
£

Fees payable to the Company's auditors for the audit of the Company's financial statements
41,350
39,750

Fees payable to the Company's auditors in respect of:

All non-audit services not included above
8,640
8,305


7.


Employees

Staff costs, including Directors' remuneration, were as follows:


2025
2024
£
£



Wages and salaries
2,925,654
2,548,495

Social security costs
362,802
289,861

Cost of defined contribution scheme
60,217
39,520

3,348,673
2,877,876





The average monthly number of employees, including the Directors, during the year was as follows:


2025
2024
No.
No.



Employees
48
42

During the year, the key management personnel of the Company received remuneration of £993,471 (2024: £993,694). 
During the year, retirement benefits were accruing to 5 key management personnel (2024: 5) in respect of defined contributions pension schemes. The Company's contributions to defined contributions pension schemes in relation to these key management personnel totalled £9,356 (2024: £6,605). 

- 22 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

8.


Directors' remuneration

2025
2024
£
£

Directors' emoluments
484,923
474,869

Company contributions to defined contribution pension schemes
3,742
2,642

488,665
477,511


During the year retirement benefits were accruing to 2 Directors (2024: 2) in respect of defined contribution pension schemes.

The highest paid Director received remuneration of £388,404 (2024: £330,946).

The value of the Company's contributions paid to a defined contribution pension scheme in respect of the highest paid Director amounted to £1,871 (2024: £2,642).


9.


Interest receivable

2025
2024
£
£


Other interest receivable
1,256
18,501


10.


Interest payable and similar expenses

2025
2024
£
£


Loans from group undertakings
158,934
129,955


11.


Taxation


2025
2024
£
£



Total current tax
-
-

Deferred tax

Total deferred tax
-
-


Taxation on profit on ordinary activities
-
-
- 23 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
 
11.Taxation (continued)


Factors affecting tax charge for the year

The tax assessed for the year is higher than (2024: higher than) the standard rate of corporation tax in the UK of25% (2024: 25%). The differences are explained below:

2025
2024
£
£


Loss on ordinary activities before tax
(1,939,902)
(1,549,046)


Loss on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2024: 25%)
(484,976)
(387,262)

Effects of:


Expenses not deductible for tax purposes
63,496
83,256

Other permanent differences
(3,615)
(7,711)

Deferred tax not recognised
425,095
311,717

Total tax charge for the year
-
-


Factors that may affect future tax charges

There are no factors that may affect future tax charges.

- 24 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

12.


Tangible assets





Furniture, fittings and equipment

£



Cost


At 1 January 2025
86,483


Additions
70,566


Disposals
(8,016)



At 31 December 2025

149,033



Depreciation


At 1 January 2025
74,804


Charge for the year 
15,080



At 31 December 2025

89,884



Net book value



At 31 December 2025
59,149



At 31 December 2024
11,679

- 25 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

13.


Fixed asset investments





Investments in subsidiary companies

£



Cost and net book value


At 1 January 2025
130


Disposals
(129)



At 31 December 2025
1





Subsidiary undertaking


The following was a subsidiary undertaking of the Company:

Name

Registered office

Principal activity

Class of shares

Holding

RMI Global Solutions Guyana Inc
GYSBI Industrial Estate 
Lots 1 & 2, Area ‘X’ Plantation Houston 
East Bank Demerara, Guyana
Supporting operating and managing risk through medical, security and technical services.
Ordinary
49%


14.


Stocks

2025
2024
£
£

Finished goods and goods for resale
47,460
-



15.


Debtors: Amounts falling due within one year

2025
2024
£
£


Trade debtors
1,367,288
2,137,892

Amounts owed by group undertakings
754,438
3,598,631

Other debtors
90,264
47,871

Prepayments and accrued income
166,490
335,800

2,378,480
6,120,194


- 26 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

15.Debtors: Amounts falling due within one year (continued)

Amounts owed by group undertakings are unsecured, payable on demand and interest free. 
Trade debtors are stated at net of a provision of £37,627 (2024: £59,550).


16.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
97,781
329,870



17.


Creditors: Amounts falling due within one year

As restated
2025
2024
£
£

Trade creditors
539,401
683,534

Amounts owed to group undertakings
5,824,335
7,612,942

Other taxation and social security
152,411
276,004

Other creditors
116,921
158,746

Accruals and deferred income
297,189
190,248

6,930,257
8,921,474


Included in amounts owed to group undertakings is an amount of £1,500,000 (2024: £1,500,000) which is unsecured, repayable on demand and interest bearing at 8% (2024: 8%) per annum. The remaining amounts included in amounts owed to group undertakings are unsecured, repayable on demand and interest free. 

- 27 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

18.


Financial instruments

As restated
2025
2024
£
£

Financial assets


Financial assets that are debt instruments measured at amortised cost
2,526,001
6,450,064


Financial liabilities


Financial liabilities that are debt instruments measured at amortised cost
6,929,691
8,921,474


Financial assets that are debt instruments measured at amortised cost comprise of trade debtors, amounts owed by group undertakings, other debtors and cash and cash equivalents. 


Financial liabilities that are debt instruments measured at amortised cost comprise of trade creditors, amounts owed to group undertakings, other creditors and accruals. 


19.


Called up share capital

2025
2024
£
£
Allotted, called up and fully paid



1 (2024: 1) ordinary share of £1
1
1

The Company has one class of ordinary shares; each share has attached to it full voting, dividend and capital distribution rights.



20.


Reserves

Capital contribution reserve

The capital contribution reserve represents amounts arising from the waiver of intercompany balances.

Profit and loss account

This reserve represents the cumulative profits and losses of the Company. 
- 28 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

21.


Share based payments

The parent entity Remote Medicine Inc operates a share scheme to certain members of the Company. In total 5 employees were awarded options. The contractual life of each option is 10 years. Options are exercisable at the vesting date. No performance conditions were included in the fair value calculations. The Black Scholes options pricing model was used to value the share based payment awards as it was considered that this approach would result in materially accurate estimate of the fair value of options granted. The entity measures its share based payment expense on the basis of allocation of the expense from the group. The basis is set on the overall allocation of options.
During the year, no new share options (2024: None) were granted to employees of the entity.
There was a repricing exercise performed in 2022 which resulted in an uplift of £110k in the valuation. No repricing exercising performed in 2025.
Options over shares in the Company have been awarded to certain employees as follows:

Weighted average exercise price (pence)
2025
Number
2025
Weighted average exercise price
(pence)
2024
Number
2024

Outstanding at the beginning of the year

8.71

182,049

8.71
 
182,049
 
Granted during the year

-

-

 
-
 
Outstanding at the end of the year
8.71

182,049

8.71
 
182,049
 

2025
2024

Weighted average share price ($)


6.55

8.82
 
Exercise price ($)


13.22

7.2
 
Weighted average contractual life (years)


5.54

6.54
 
Expected volatility


77.1%

73%
 
Expected dividend growth rate


Nil

Nil
 

2025
2024
£
£



Expense recognised during the year
252,792
309,656

Equity-settled schemes
1,328,661
1,075,868

- 29 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

22.


Prior period error

During the year, management identified an error in the historic intercompany balances. This error arose following the migration to a new IT system in 2018 and relates to periods before 1 January 2024. As the error relates to periods before 1 January 2024, the correction has been recognised as an adjustment to opening retained earnings at 1 January 2024, together with a corresponding adjustment to the intercompany liability.

There is no impact on the Statement of Comprehensive Income for the year ended 31 December 2024. However, because the correction relates to balances that remained outstanding, the adjustment has a cumulative impact on the Statement of Financial Position balances as at 31 December 2024.

The table below summaries the prior period error correction adjustments.

Statement of Financial position - for the year ended 31 December 2024



As previously reported as at 1 January 2024
£

Adjustment
£
Restated as at 1 January 
2024
£






Creditors: amounts falling due within one year
(9,604,987)
683,513
(8,921,474)

Reserves
3,143,115
(683,513)
2,459,602





The impact of the above restatement for the year ended 31 December 2024 is a decrease in the creditors due within one year of £683,513 and an increase in reserves of £683,513. There was no impact on the Statement of Comprehensive Income for the year ended 31 December 2024.


23.


Pension commitments

The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £60,217 (2024: £39,520). Contributions payable to the fund at the year end amounted to £9,089 (2024: £Nil).


24.


Commitments under operating leases

At 31 December 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£


Not later than 1 year
44,124
43,927

Later than 1 year and not later than 5 years
7,635
-

51,759
43,927

- 30 -

 
REMOTE MEDICAL INTERNATIONAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

25.


Related party transactions

At the year end, the Company owed an amount of £64,101 (2024: £65,356) to Remote Medical International Ghana Limited, a group company incorporated in Ghana. This amount is included in amounts owed to group undertakings. 
During the year the Company entered into transaction with of RMI Global Solutions Guyana Inc. Remote Medical International UK Limited owns 49% of the shares of this entity. Management fees to the entity totalled £205,939 (2024: £239,409), purchases of £Nil (2024: £Nil), debtors of £436,414 (2024: £161,804) and creditors of £Nil (2024: £Nil).
The Company has taken advantage of the exemption under section 33 of FRS 102 from disclosing related party transactions undertaken between wholly owned members of the group. 
The Company has 49% control with significant influence of RMI Global Solutions Guyana Limited. The Company has taken the exemption to consolidate this subsidiary.


26.


Post balance sheet events

There have been no significant events affecting the Company since the year end.


27.


Controlling party

The immediate and ultimate parent company is Remote Medicine Inc. a company incorporated in the USA. Its registered office address is 1455 NW Leary Way, Suite 400, Seattle, WA 98107, USA. 
The ultimate controlling party is considered to be Brandon Baty due to his majority shareholding in Remote Medicine Inc. 
The smallest and largest group which prepares consolidated financial statements in which the Company is included is Remote Medicine Inc. Copies of the consolidated financial statements are not publicly available.

- 31 -